The global anti-infective vaccines market was valued at around US$ 51.0 Billion at the end of 2021. The market is projected to register a 12.3% CAGR and top a valuation of US$ 168.7 Billion by 2032.
The anti-infective vaccines market will grow substantially as the epidemiological burden of infectious diseases increases worldwide.
Vaccines function by exposing the immune system to disease-causing pathogens (bacteria or viruses) that are dead or weak, vaccines help lower the risk of certain illnesses and infections. This process increases the development of antibodies, which can offer immunity against one or more diseases and infections.
Depending on the immune system's reaction to the vaccine introduction and the needs of the target patient. There are many different types of vaccines for different applications for treating infections such as bacterial/viral infection and influenza, including inactivated vaccines, live/attenuated vaccines, and conjugate vaccines.
| Attributes | Details |
|---|---|
| Anti-Infective Vaccines Market Value in 2021 | US$ 51.0 Billion |
| Anti-Infective Vaccines Market Value in 2032 | US$ 168.7 Billion |
| Anti-Infective Vaccines Market CAGR (2022 to 2032) | 12.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
A growing population at risk for various infections, the advent of antibiotic-resistant pathogenic organisms, and the ongoing discovery of novel pathogens all constitute a significant challenge to public health. Given the clear and rising risk of pandemic disease and the risk of infection, the development of vaccinations that optimize protective immunity against such organisms constitutes an urgent need for anti-infective vaccine research. Over the forecast period, all of these variables are anticipated to fuel the market expansion for anti-infective vaccines.
The prevalence of infectious diseases strains society socially and financially. For instance, each year, millions of individuals are affected by influenza, which lowers productivity and causes financial losses. Governments are now recognizing the severity of influenza as a serious illness that increases healthcare costs and places a financial strain on the government.
Furthermore, the same is true for the different infectious diseases that can be prevented with vaccination, including meningitis, pneumococcal disease, and infectious disorders like hepatitis, meningitis, and pneumococcus. Governments are aiming to broaden their vaccination programs in order to increase immunization coverage rates among the population who are the backbone of the economy. In the future, the anti-infective vaccines market is anticipated to be influenced by the aforementioned considerations.
The anti-infective vaccines market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America is the leading region in the global anti-infective vaccines market owing to better awareness among people about health care and the advanced treatment options for the treatment of a number of infections region.
Apart from North America, the European anti-infective vaccines market is also expected to display lucrative growth in the projected years because of the presence of major players in the industry
The East Asian region is predicted to show lucrative growth owing to the growing geriatric population and rising prevalence of infections.
Principal Consultant
Sanofi Pasteur, Merck & Co., MedImmune LLC, Novartis Vaccines, Diagnostics Ltd., Intercell Biomedical, MassBiologics, Barr Labs, Inc., Organon Teknika Co., Emergent BioDefense Operations Lansing Inc., CSL Ltd., ID Biomedical Co., Protein Sciences Co.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 12.3% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segment Covered | Type, Application, Distribution Channel, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Players | Sanofi Pasteur; Merck & Co.; MedImmune LLC; Novartis Vaccines; Diagnostics Ltd.; Intercell Biomedical; MassBiologics; Barr Labs, Inc.; Organon Teknika Co.; Emergent BioDefense Operations Lansing Inc.; CSL Ltd.; ID Biomedical Co.; Protein Sciences Co. |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global anti-infective vaccines market is anticipated to register a CAGR of 12.3% during the forecast period.
The global anti-infective vaccines market is projected to be about US$ 168.7 Billion by the end of the year 2032.
Explore Healthcare Insights
View Reports
Anti-Infective Vaccines Market
